Ribozymes

Pc, Turner

doi:10.1007/0-306-46817-4_26

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2003

2013

Publication Types

Select...

Article4

Book1

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 9 publications

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

pcDNA3.1(−)-mediated ribozyme targeting of HER-2 suppresses breast cancer tumor growth

Zhu

et al. 2009

Mol Biol Rep

View full text Add to dashboard Cite

The HER-2 proto-oncogene (also called c-erbB-2/neu) encodes the protein, p185, which is closely related to the growth and metastasis of adenocarcinoma, and is overexpressed in 25-30% of human breast cancers. In this study, we attempt to reverse the malignant phenotype of the breast cancer cell line, MCF-7, using a HER-2-specific hammerhead ribozyme. Two anti-HER-2 hammerhead ribozymes, RZ1 and RZ2, were synthesized, inserted separately into the nonviral eukaryotic expression vector, pcDNA3.1(-), and transfected into MCF-7 cells. Analyses showed that the HER-2 mRNA and p185, as well as oncogene k-ras were down-regulated remarkably in the ribozyme-transfected cells, while the onco-suppressor gene, p53, was up-regulated. Furthermore, the tumorigenicity of the RZ1-stably transfected MCF-7 cells was decreased dramatically in nude mice. These results demonstrate that the use of anti-HER-2 ribozymes may be a beneficial strategy for gene therapy of breast cancer.

show abstract